Disrupting the CD47–SIRPα interaction bridges innate and adaptive antitumor immune mechanisms [9, 13]; therefore, we determined the activity of hAB21 in multiple syngeneic murine tumor models as a monotherapy or in combination with immune checkpoint inhibitors. This evidence concerns the gene CD47 and neoplasm.